Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA4 | SAM.gov Opportunity | G2X

Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA4

SolicitationDARPA-SN-26-91Notice typeSpecial Notice

Attachments

1 file

Name	Type	Posted	Actions
DARPA-SN-26-91.pdf	PDF	Jun 11, 2026	Download

Version History

Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA4

Special NoticeDARPA-SN-26-91Jun 11, 2026 · v2

LatestViewing

Opportunity Summary

The Defense Advanced Research Projects Agency (DARPA) is seeking support for the commercialization of technologies developed under the upcoming Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program. This special notice, issued under solicitation number DARPA-SN-26-91, serves to notify the community of RAPIID commercialization goals, initiate dialogue regarding program needs, and establish the timetable for full proposal submissions. The effort is managed by LCDR Robert Murray of the Biological Technologies Office (BTO) and is released under the DARPA BTO Office Wide Broad Agency Announcement (BAA) HR001126S0003, titled “Biological Technologies.”

The acquisition is classified under NAICS 541714: Research and Development in Biotechnology (except Nanobiotechnology) and PSC AC12: National Defense R&D Services; Department of Defense - Military; Applied Research. Responses are due by June 29, 2026. The notice includes one attachment, a PDF document titled DARPA-SN-26-91.pdf, which was published and updated on June 11, 2026. No specific set-aside was designated for this announcement.

Generated by Lumen AI

Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.

Opportunity Summary

Opportunity Details

Response deadline: Jun 29, 202613 days remaining
NAICS: 541714 (opens in new tab)
PSC: AC12 (opens in new tab)
Set aside: —
Published: Jun 11, 2026
Updated: Jun 11, 2026
Agency: DEPARTMENTAL OFFICES (opens in new tab)
Office: INVALID
Department: —
Source: View on SAM.gov (opens in new tab)

Contact and place of performance

Point of contact: LCDR Robert Murray, Program Manager, DARPA/BTO

Place of performance: Not specified

Original Description

The Defense Advanced Research Projects Agency (DARPA) is seeking support for commercialization of technologies to be developed under the upcoming Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program.

The purpose of this announcement is to notify the community of the RAPIID commercialization goals, initiate dialogue to address program needs, and share the timetable for full proposal submission.

This special notice is released under the current DARPA BTO Office Wide Broad Agency Announcement (BAA) HR001126S0003, titled “Biological Technologies.”